Immune Checkpoint Inhibitor Therapy May Reduce Asthma Exacerbations
PR Newswire —
Patients receiving pembrolizumab or nivolumab exhibited a modest reduction in asthma exacerbation rates at 24 months MILWAUKEE, Feb. 16, 2026 /PRNewswire/ -- Immune checkpoint inhibitors (ICIs) were associated with modest protective effects for patients with asthma, according to new...